Health Watchdog Advises Regular Monitoring for PMOS
A leading health watchdog has proposed that women diagnosed with Polyendocrine Metabolic Ovarian Syndrome (PMOS) undergo annual health checks within the NHS. This recommendation aims to facilitate earlier detection and better management of the diverse health issues associated with this complex condition.
Understanding PMOS: A Renamed Condition
PMOS, which impacts approximately one in eight women, was formerly known as polycystic ovary syndrome. The name change, implemented in May, reflects a broader understanding of its systemic effects throughout the body. The National Institute for Health and Care Excellence (NICE), in its draft guidance, advocates for quicker diagnoses and more consistent monitoring of the condition.
Key symptoms of PMOS, as outlined by the NHS, include:
- Irregular or absent menstrual periods
- Difficulties with conception
- Excessive hair growth on the face and body
- Weight gain
- Hair loss from the scalp
- Oily skin or acne
Despite affecting an estimated three to four million women in the UK, PMOS often remains under-diagnosed and inconsistently managed, according to NICE, which evaluates the cost-effectiveness of NHS treatments.
Comprehensive Annual Checks and Long-Term Risks
The new guidelines suggest that annual checks should not only focus on the primary symptoms but also assess associated long-term health risks, such as diabetes and heart disease. NICE emphasizes that lifestyle adjustments, alongside medical treatments, can play a crucial role in preventing more severe health complications. While there is no cure for PMOS, the NHS currently provides various treatments to manage symptoms, including hormonal support and fertility medications.
However, the new guidance explicitly states that laser and light therapies for hair reduction are not recommended due to their cost.
Patient Experience Highlights Diagnosis Challenges
"It was so disheartening to be told, until I was finally diagnosed in my mid-30s, that my symptoms were just part of being a woman." - Sharon Manship
Sharon Manship, who lives with PMOS and contributed to the new guidelines, shared her struggle to receive a diagnosis. Despite seeking medical help in her early 20s, it took over a decade for her condition to be identified. Her experience mirrors that of many women who face delays and difficulties in understanding their symptoms and obtaining a diagnosis.
When PMOS is suspected, medical professionals may use blood tests to evaluate hormone levels and ultrasound scans to identify the numerous follicles frequently observed in the ovaries of affected individuals.
Broader Considerations and Mental Health Impact
The NICE guideline also provides recommendations on when to suspect PMOS, how to assess women, and how to diagnose the condition, including its potential presence in post-menopausal women. It notes that PMOS may be more prevalent among women of Black, Asian, and mixed ethnic backgrounds, urging healthcare professionals to consider this during symptom assessment.
Living with PMOS can significantly affect mental health and overall quality of life, with the draft guidelines highlighting the common occurrence of depression and anxiety. For those planning a pregnancy, advice on weight management, diet, nutrition, exercise, sleep, and mental well-being is also recommended.
Marie Anne Ledingham, consultant clinical advisor for women's and reproductive health at NICE, described the recommendation for a "simple" annual review as a significant step forward. She anticipates that the new guideline will enhance consistency in care, raise awareness of the condition, and support earlier diagnosis and management.
The draft guideline is currently open for public consultation until August 11, 2026, with the final version expected to be published in December 2026.
Source: Original Article